1-15 of 15
Mark R. Gilbert
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases

Sarah Jenkins, Wei Zhang, Seth M. Steinberg, Darryl Nousome, Nicole Houston, Xiaolin Wu, Terri S. Armstrong, Eric Burton, Dee Dee Smart, Ritu Shah, Cody J. Peer, Brett Mozarsky, Oluwatobi Arisa, William D. Figg, Tito R. Mendoza, Elizabeth Vera, Priscilla Brastianos, Scott Carter, Mark R. Gilbert, Carey K. Anders, Roisín M. Connolly, Carol Tweed, Karen L. Smith, Imran Khan, Stanley Lipkowitz, Patricia S. Steeg, Alexandra S. Zimmer
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1450–1459.
https://doi.org/10.1158/1078-0432.CCR-22-0855
Published: 14 April 2023
View article titled, Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases
Open the PDF for Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases in another window
Includes: Supplementary data
Journal Articles

Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis via Nrf2

Yang Liu, Fu-Ju Chou, Fengchao Lang, Meili Zhang, Hua Song, Wei Zhang, Dionne L. Davis, Nicole J. Briceno, Yang Zhang, Patrick J. Cimino, Kareem A. Zaghloul, Mark R. Gilbert, Terri S. Armstrong, Chunzhang Yang
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (7): 1305–1316.
https://doi.org/10.1158/1078-0432.CCR-22-3179
Published: 03 April 2023
View article titled, Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis via Nrf2
Open the PDF for Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis via Nrf2 in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas

Jing Wu, Ying Yuan, Debra A. Long Priel, Danielle Fink, Cody J. Peer, Tristan M. Sissung, Yu-Ting Su, Ying Pang, Guangyang Yu, Madison K. Butler, Tito R. Mendoza, Elizabeth Vera, Salman Ahmad, Christine Bryla, Matthew Lindsley, Ewa Grajkowska, Kelly Mentges, Lisa Boris, Ramya Antony, Nancy Garren, Christine Siegel, Nicole Lollo, Christine Cordova, Orwa Aboud, Brett J. Theeler, Eric M. Burton, Marta Penas-Prado, Heather Leeper, Javier Gonzales, Terri S. Armstrong, Katherine R. Calvo, William D. Figg, Douglas B. Kuhns, John I. Gallin, Mark R. Gilbert
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (12): 3298–3306.
https://doi.org/10.1158/1078-0432.CCR-20-4730
Published: 15 June 2021
View article titled, Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
Open the PDF for Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas in another window
Includes: Multimedia, Supplementary data
Journal Articles

Translating Basic Science Discoveries into Improved Outcomes for Glioblastoma

Peter B. Dirks, Mark R. Gilbert, Eric C. Holland, Elizabeth A. Maher, William A. Weiss
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11): 2457–2460.
https://doi.org/10.1158/1078-0432.CCR-19-3924
Published: 01 June 2020
View article titled, Translating Basic Science Discoveries into Improved Outcomes for Glioblastoma
Open the PDF for Translating Basic Science Discoveries into Improved Outcomes for Glioblastoma in another window
Journal Articles

Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism

Varun V. Prabhu, Neel S. Madhukar, Coryandar Gilvary, C. Leah B. Kline, Sophie Oster, Wafik S. El-Deiry, Olivier Elemento, Faye Doherty, Alexander VanEngelenburg, Jessica Durrant, Rohinton S. Tarapore, Sean Deacon, Neil Charter, Jinkyu Jung, Deric M. Park, Mark R. Gilbert, Jessica Rusert, Robert Wechsler-Reya, Isabel Arrillaga-Romany, Tracy T. Batchelor, Patrick Y. Wen, Wolfgang Oster, Joshua E. Allen
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (7): 2305–2313.
https://doi.org/10.1158/1078-0432.CCR-18-2572
Published: 01 April 2019
View article titled, Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism
Open the PDF for Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism in another window
Includes: Supplementary data
Journal Articles

MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials

Monika E. Hegi, Els Genbrugge, Thierry Gorlia, Roger Stupp, Mark R. Gilbert, Olivier L. Chinot, L. Burt Nabors, Greg Jones, Wim Van Criekinge, Josef Straub, Michael Weller
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (6): 1809–1816.
https://doi.org/10.1158/1078-0432.CCR-18-3181
Published: 15 March 2019
View article titled, <em>MGMT</em> Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials
Open the PDF for <em>MGMT</em> Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Novel Targeting of Transcription and Metabolism in Glioblastoma

Yu-Ting Su, Robert Chen, Herui Wang, Hua Song, Qi Zhang, Li-Yuan Chen, Hallie Lappin, Gabriel Vasconcelos, Adrian Lita, Dragan Maric, Aiguo Li, Orieta Celiku, Wei Zhang, Kristan Meetze, Thomas Estok, Mioara Larion, Mones Abu-Asab, Zhengping Zhuang, Chunzhang Yang, Mark R. Gilbert, Jing Wu
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (5): 1124–1137.
https://doi.org/10.1158/1078-0432.CCR-17-2032
Published: 28 February 2018
View article titled, Novel Targeting of Transcription and Metabolism in Glioblastoma
Open the PDF for Novel Targeting of Transcription and Metabolism in Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials

Ying Yuan, Kenneth R. Hess, Susan G. Hilsenbeck, Mark R. Gilbert
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (17): 4291–4301.
https://doi.org/10.1158/1078-0432.CCR-16-0592
Published: 31 August 2016
View article titled, Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials
Open the PDF for Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials in another window
Includes: Supplementary data
Journal Articles

Genetic Modulation of Neurocognitive Function in Glioma Patients

Yanhong Liu, Renke Zhou, Erik P. Sulman, Michael E. Scheurer, Nicholas Boehling, Georgina N. Armstrong, Spiridon Tsavachidis, Fu-Wen Liang, Carol J. Etzel, Charles A. Conrad, Mark R. Gilbert, Terri S. Armstrong, Melissa L. Bondy, Jeffrey S. Wefel
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (14): 3340–3346.
https://doi.org/10.1158/1078-0432.CCR-15-0168
Published: 14 July 2015
View article titled, Genetic Modulation of Neurocognitive Function in Glioma Patients
Open the PDF for Genetic Modulation of Neurocognitive Function in Glioma Patients in another window
Includes: Supplementary data
Journal Articles

Facing the Future of Brain Tumor Clinical Research

Mark R. Gilbert, Terri S. Armstrong, Whitney B. Pope, Martin J. van den Bent, Patrick Y. Wen
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5591–5600.
https://doi.org/10.1158/1078-0432.CCR-14-0835
Published: 13 November 2014
View article titled, Facing the Future of Brain Tumor Clinical Research
Open the PDF for Facing the Future of Brain Tumor Clinical Research in another window
Journal Articles

Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03

Eudocia Q. Lee, Vinay K. Puduvalli, Joel M. Reid, John G. Kuhn, Kathleen R. Lamborn, Timothy F. Cloughesy, Susan M. Chang, Jan Drappatz, W. K. Alfred Yung, Mark R. Gilbert, H. Ian Robins, Frank S. Lieberman, Andrew B. Lassman, Renee M. McGovern, Jihong Xu, Serena Desideri, Xiabu Ye, Matthew M. Ames, Igor Espinoza-Delgado, Michael D. Prados, Patrick Y. Wen
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (21): 6032–6039.
https://doi.org/10.1158/1078-0432.CCR-12-1841
Published: 06 November 2012
View article titled, Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03
Open the PDF for Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03 in another window
Includes: Supplementary data
Journal Articles

Polymorphisms in the Interleukin-4 Receptor Gene are Associated with Better Survival in Patients with Glioblastoma

Michael E. Scheurer, E. Amirian, Yumei Cao, Mark R. Gilbert, Kenneth D. Aldape, David G. Kornguth, Randa El-Zein, Melissa L. Bondy
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (20): 6640–6646.
https://doi.org/10.1158/1078-0432.CCR-07-4681
Published: 16 October 2008
View article titled, Polymorphisms in the <em>Interleukin-4 Receptor</em> Gene are Associated with Better Survival in Patients with Glioblastoma
Open the PDF for Polymorphisms in the <em>Interleukin-4 Receptor</em> Gene are Associated with Better Survival in Patients with Glioblastoma in another window
Journal Articles

Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms

Arnab Chakravarti, Michael G. Erkkinen, Ulf Nestler, Roger Stupp, Minesh Mehta, Ken Aldape, Mark R. Gilbert, Peter McL. Black, Jay S. Loeffler
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (15): 4738–4746.
https://doi.org/10.1158/1078-0432.CCR-06-0596
Published: 09 August 2006
View article titled, Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms
Open the PDF for Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms in another window
Journal Articles

Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01

Andrew B. Lassman, Michael R. Rossi, Jeffrey R. Razier, Lauren E. Abrey, Frank S. Lieberman, Chelsea N. Grefe, Kathleen Lamborn, William Pao, Alan H. Shih, John G. Kuhn, Richard Wilson, Norma J. Nowak, John K. Cowell, Lisa M. DeAngelis, Patrick Wen, Mark R. Gilbert, Susan Chang, W.A. Yung, Michael Prados, Eric C. Holland
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7841–7850.
https://doi.org/10.1158/1078-0432.CCR-05-0421
Published: 08 November 2005
View article titled, Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
Open the PDF for Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01 in another window
Includes: Supplementary data
Journal Articles

Phase I Clinical and Pharmacokinetic Study of Irinotecan in Adults with Recurrent Malignant Glioma

Mark R. Gilbert, Jeffrey G. Supko, Tracy Batchelor, Glenn Lesser, Joy D. Fisher, Steven Piantadosi, Stuart Grossman
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (8): 2940–2949.
Published: 11 August 2003
View article titled, Phase I Clinical and Pharmacokinetic Study of Irinotecan in Adults with Recurrent Malignant Glioma
Open the PDF for Phase I Clinical and Pharmacokinetic Study of Irinotecan in Adults with Recurrent Malignant Glioma in another window